GlaxoSmithKline Says Daprodustat Drug Gets EU Marketing Authorization
01 March 2022 - 6:42PM
Dow Jones News
By Sabela Ojea
GlaxoSmithKline PLC said Tuesday that its drug Daprodustat has
received marketing authorization by the European Medicines
Agency.
The company said its application was accepted for review by the
EMA.
The drug Daprodustat, aimed at treating anaemia of chronic
kidney disease, is currently approved in Japan, the FTSE 100-listed
company said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
March 01, 2022 02:27 ET (07:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024